Moroctocog alfa biosimilar (Amega Biotech)

莫罗凝血素生物类似药 (Amega Biotech)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMoroctocog alfa biosimilar (Amega Biotech)

Drug Alias Namerecombinant Factor VIII glycoprotein莫罗凝血素生物仿制药 (Amega Biotech)

ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant coagulation factorBiologics > Biosimilar

Mechanisms of ActionCoagulation factor VIII replacementsCoagulation factor X stimulantsBlood coagulation pathway activation

TargetsCoagulation factor X

Therapy Area/IndicationsHemophilia A

Global Approved IndicationsHemophilia A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryArgentina

Original Approved Date2012/01/01

Country/TerritoryArgentina

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesAmega Biotech

China Registration ClassN/A

Active CompaniesAmega Biotech

Inactive CompaniesN/A

Active IndicationsHemophilia A

Inactive IndicationsN/A

ATC CodeB02BD02